Health Update Bahamas: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Update Bahamas.

September 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Press releases published on October 8, 2025

October 8, 2025

Nilo Therapeutics se lanza con un financiamiento Serie A de 101 millones de dólares para avanzar una nueva clase de medicamentos dirigidos a los circuitos neuronales en enfermedades inmunológicas y nombra a Kim Seth como director ejecutivo

GlobeNewswire

October 8, 2025

Lancement de Nilo Therapeutics avec un financement de série A de 101 millions de dollars en vue de développer une nouvelle classe de médicaments ciblant les circuits neuronaux dans les maladies immunitaires, et nomination de Kim Seth au poste de…

GlobeNewswire

October 8, 2025

ナイロ・セラピューティクス (Nilo Therapeutics)、免疫疾患における神経回路を標的とする新しい種類の医薬品開発を推進するため、1億100万米ドル (約154億1,290万円) のシリーズA資金調達を実施し、キム・セス博士 (Kim Seth, Ph.D.) を最高経営責任者 (CEO) に任…

GlobeNewswire

October 8, 2025

Nilo Therapeutics dilancarkan dengan pembiayaan Siri A sebanyak $101 juta untuk membangunkan kelas baharu ubat-ubatan yang menyasarkan litar neural dalam penyakit imun, serta melantik Kim Seth sebagai Ketua Pegawai Eksekutif

GlobeNewswire

October 8, 2025

Nilo Therapeutics é lançada com financiamento de US $101 milhões da Série A para promover uma nova classe de medicamentos direcionados a circuitos neurais em doenças imunológicas e nomeia Kim Seth como CEO

GlobeNewswire

October 8, 2025

Nilo Therapeutics 啟動 1.01 億美元 A 輪融資，推進針對免疫疾病神經迴路的新型藥物研發，並任命 Kim Seth 為行政總裁

GlobeNewswire

October 8, 2025

Nilo Therapeutics เปิดตัวด้วยการระดมทุนรอบ Series A มูลค่าถึง 101 ล้านเหรียญสหรัฐ เพื่อพัฒนายาประเภทใหม่ที่มุ่งเป้าไปที่วงจรระบบประสาทในโรคภูมิคุ้มกัน รวมถึงแต่งตั้ง Kim Seth เป็นประธานเจ้าหน้าที่บริหา…

GlobeNewswire

October 8, 2025

Nilo Therapeutics 启动 1.01 亿美元 A 轮融资，以推进靶向免疫疾病神经回路的新型药物研发，并任命 Kim Seth 为首席执行官

GlobeNewswire

October 8, 2025

Greenspace Herbs Unveils Physics-Driven Quantum Ayurveda at SupplySide Global

GlobeNewswire

October 8, 2025

Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV

GlobeNewswire

October 8, 2025

AMN Healthcare to Hold Third Quarter 2025 Earnings Conference Call on Thursday, November 6, 2025

GlobeNewswire

October 8, 2025

Dentsply Sirona to Host Third Quarter Conference Call on November 6th

GlobeNewswire

October 8, 2025

BrightSpring Health Services, Inc. to Announce Third Quarter 2025 Financial Results on October 31, 2025

GlobeNewswire

October 8, 2025

PetMed Express, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

October 8, 2025

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

GlobeNewswire

October 8, 2025

Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025

GlobeNewswire

October 8, 2025

Libtayo® (cemiplimab-rwlc) Approved in the U.S. as First and Only Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation

GlobeNewswire

October 8, 2025

CAR T-Cell Therapy for Multiple Myeloma Market to Witness Upsurge in Growth by 2034 Owing to the Launch of Emerging Therapies | DelveInsight

GlobeNewswire

October 8, 2025

Rheumatoid Arthritis Therapies Market to Hit $41.1B by 2030

GlobeNewswire

October 8, 2025

Kids Help Phone Sets a New Standard of Care for Youth Mental Health at Elevate 2025

GlobeNewswire